Showing 1061-1070 of 1635 results for "".
- OD-OS to Showcase Navilas Navigated Retinal Laser Therapy at EURETINAhttps://modernod.com/news/od-os-to-showcase-navilas-navigated-retinal-laser-therapy-at-euretina/2476852/OD-OS will share clinical experiences with the Navilas 577s digital treatment platform this week at the EURETINA Congress in Paris. Navigated retinal laser therapy with the Navilas 577s allows for panretinal photocoagulation with uniform spot distribution, which is faster and less painful for pat
- Alcon Names Carla Mack, OD, Global Head of Professional Affairs for Vision Carehttps://modernod.com/news/alcon-names-carla-mack-od-global-head-of-professional-affairs-for-vision-care/2476847/Alcon has announced that Carla Mack, OD, has been named Global Head, Professional Affairs. In her new role, Dr. Mack leads professional affairs within Alcon’s Global Vision Care Franchise, reporting to Andy Pawson, President and General Manager, Global Vision Care Franchise. As Global Head
- Now Optics Names Two Women to its Executive Leadership Teamhttps://modernod.com/news/now-optics-names-two-women-to-its-executive-leadership-team/2476834/Now Optics recently named two women to its leadership team. Former CVS Health’s Morgan Diaz joined Now Optics as senior vice president of operations and business development, and Lukana Justin previously from Office Depot Inc. is the new, senior vice president of marketing. They join Tara Pellegr
- National Center for Children’s Vision and Eye Health at Prevent Blindness Receives Renewed Granthttps://modernod.com/news/national-center-for-childrens-vision-and-eye-health-at-prevent-blindness-receives-renewed-grant/2476794/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH), celebrating its 10-year anniversary, has announced that a second year of funding was received from the federal Health Resources and Services Administration’s Maternal and Child Health Bureau for $300,000 to su
- BioTime Announces Name Change to Lineage Cell Therapeuticshttps://modernod.com/news/biotime-announces-name-change-to-lineage-cell-therapeutics/2479562/In a move to reflects the company’s commitment to becoming a leading cell therapy company, BioTime announced it is launching a new corporate brand, including a change of its corporate name to Lineage Cell Therapeutics, effective August 12, 2019. In connection with the launch, the com
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmologyhttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology/2476783/U.S News & World Report has once again ranked Bascom Palmer Eye Institute of the University of Miami Health System as the nation’s best in ophthalmology. Recognized as a global leader in vision research, medical education, and patient care, this year marks the 18th time that Bascom P
- Oyster Point Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-phase-3-clinical-trial-of-nasal-spray-for-dry-eye-disease/2476763/Oyster Point Pharma announced enrollment of the first subject in the phase 3 ONSET-2 clinical trial of OC-01 nasal spray for the treatment of the signs and symptoms of dry eye disease. “After successfully compl
- Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch ‘My Home In Sight’https://modernod.com/news/novartis-teams-up-with-celebrity-interior-designer-nate-berkus-to-launch-my-home-in-sight/2476753/Novartis is teaming up with celebrity interior designer Nate Berkus to launch “My Home in Sight,” a program that aims to raise awareness of the daily impact of wet age-related macular degeneration (AMD) and empower those living with wet AMD and their car
- New Software Update Expands Capabilities of the OD-OS Navilas 577shttps://modernod.com/news/new-software-update-expands-capabilities-of-the-od-os-navilas-577s/2476754/OD-OS has released a new software update for its Navilas 577s. With a new multimodal “export wizard,” retina specialists can generate high resolution images of their treatments in different configurations. This allows for advanced, transparent documentation for all purposes and record
- Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMAhttps://modernod.com/news/omeros-announces-agreement-with-fda-on-primary-endpoint-for-narsoplimab-bla-in-stem-cell-transplant-associated-tma/2476724/Omeros announced agreement with the FDA on the response-based primary endpoint for its pivotal trial to support the biologics license application (BLA) for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), ac